Gastrointestinal stromal tumors and leiomyosarcomas

J Surg Oncol. 2008 Mar 15;97(4):350-9. doi: 10.1002/jso.20970.


Only recently has gastrointestinal stromal tumor (GIST) been recognized as the most frequent GI mesenchymal neoplasm. Prior to the use of KIT staining, most GI stromal tumors were identified as leiomyosarcoma (LMS). For primary GIST, surgery remains the principal treatment and adjuvant imatinib may improve outcomes. Multimodality therapy may also be effective in patients with metastatic GIST. In this review, we summarize the epidemiology, clinicopathologic features, natural history, and clinical management of LMS and GIST.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Combined Modality Therapy
  • Gastrointestinal Stromal Tumors / diagnosis*
  • Gastrointestinal Stromal Tumors / epidemiology
  • Gastrointestinal Stromal Tumors / pathology
  • Gastrointestinal Stromal Tumors / therapy*
  • Humans
  • Leiomyosarcoma / diagnosis*
  • Leiomyosarcoma / epidemiology
  • Leiomyosarcoma / pathology
  • Leiomyosarcoma / therapy*
  • Prognosis